Global Parkinson's Disease Market to Drop by $0.5 Billion by 2019, Says Report

December 18, 2013
Julian Upton

Julian Upton is Pharmaceutical Executive's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Pharmaceutical Executive

The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).

The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).

With PD drugs such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone) set to lose their patents by the end of the forecast period, even the approval and launch of late-stage pipeline drugs for PD, including Rytary, safinamide and pimavanserin, “won’t be significant enough to diminish the impact of generic erosion,” says GBI Research Analyst Angel Wong.

However, disease-modifying treatment for PD remains an urgent unmet need. But with 87% of neuroprotective treatments still in early-stage development, these medications face several challenges, not least “the need for a reliable biomarker that can accelerate such development,” adds Wong.

To access the GBI Research report, click here.

Related Content:

News